WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, today announced at the mHealth Summit that it is expanding the beta program for its Patient Instructions feature, which enables physicians who use Medscape Mobile to securely send education and instructions on thousands of conditions, procedures and drugs to their patients who use the WebMD app for iPhone, or access WebMD on a PC or other mobile device. The company also previewed a forthcoming version of its WebMD app that leverages the 2net™ Platform from Qualcomm Life, Inc., a subsidiary of Qualcomm Incorporated (NASDAQ: QCOM), to enable health-conscious consumers to access and manage wireless health data from a wide array of fitness, wellness and medical devices directly from the app.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60050-webmd-accelerates-consumer-provider-connectivity-personalized-mobile-app
CVS Caremark (NYSE: CVS) announced today that it will stop selling cigarettes and other tobacco products at its more than 7,600 CVS/pharmacy stores across the U.S. by October 1, 2014, making CVS/pharmacy the first national pharmacy chain to take this step in support of the health and well-being of its patients and customers.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65510-cvs-caremark-to-stop-selling-tobacco-products-at-cvs-pharmacy-locations
Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso® (brimonidine) 3 mg/g gel.
Mirvaso® is an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours.1 It is indicated for the symptomatic treatment of facial erythema (redness) of rosacea in adult patients.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65011-mirvaso-first-and-only-treatment-rosacea
The Asthma and Allergy Foundation of America (AAFA) and Teva Respiratory announced today the launch of a national awareness campaign – Know Your Count – aimed at raising awareness of the seriousness of asthma and educating asthma patients and caregivers about the importance of keeping track of the remaining doses in their rescue inhalers. The campaign features award-winning singer and actress, Kristin Chenoweth, who is speaking publicly for the first time about the impact her asthma has had on her professional career and busy lifestyle. For more information about the Know Your Count campaign, Kristin’s experience with asthma and to view an important public service announcement (PSA), visit www.KnowYourCount.com.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/65058-teva-respiratory-aafa-know-your-count-managing-asthma/
Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ® (lorcaserin HCl) CIV, an FDA-approved prescription therapy for chronic weight management. The advertisement will air on numerous channels including Lifetime, Oxygen and AMC.
The spot illustrates the struggles many people face when they are trying to lose or control their weight. BELVIQ is presented as a targeted approach to weight loss, that, when combined with diet and increased activity, may help some patients lose weight and keep it off.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7161051-eisai-launches-national-television-campaign-belviq-lorcaserin-hcl-civ
Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) (“DelMar Pharma” or “DelMar”) discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing new therapies for patients with little to no treatment options.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7037951-delmar-pharmaceuticals-glioblastoma-brain-tumor-awareness-month
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
‘Tackling hepatitis C: Moving towards an integrated policy approach’, a report published by The Economist Intelligence Unit (EIU) today reveals that many countries around the world have been slow to respond with national policies on hepatitis C despite recent government pledges to fight the disease. The hepatitis C virus remains the leading cause of liver cancer, liver disease and liver transplantation placing a huge burden on patients' lives and healthcare systems.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/71400562-janssen-new-reports-hepatitis-c
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.
The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256451-edwards-fda-clearance-for-noninvasive-hemodynamic-monitoring-system/
The following statement is being issued by Jonathan Schochor, Chairman, Plaintiffs’ Steering Committee, regarding Jane Doe No. 1, et. al. v. Johns Hopkins Hospital, et al., No. 24-C-13-001041.
If you were a patient of, or were treated by Johns Hopkins Hospital gynecologist, Dr. Nikita Levy, you may be eligible for compensation from a class action Settlement
A $190 million dollar proposed Settlement has been reached that offers payments to eligible members of The Levy Settlement Class.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7281851-dr-nikita-levy-patients-class-action-settlement/
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
CVS Caremark Corporation (NYSE: CVS) announced today that it is changing its corporate name to CVS Health to reflect its broader health care commitment and its expertise in driving the innovations needed to shape the future of health.
As a further demonstration of its commitment to health, CVS Health also announced the end of tobacco sales at CVS/pharmacy as of September 3, nearly a month ahead of the previously targeted date of October 1. In February, the company announced that it would end the sale of cigarettes and tobacco products at its CVS/pharmacy stores, making CVS/pharmacy the first and only national pharmacy chain to take this step in support of the health and well-being of its patients and customers.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7308951-cvs-caremark-announces-corporate-name-change-to-cvs-health/
